_1b78fec41a5143afb6e7b9ad317023d2-620x480.jpg "Hepatitis C infection associated with reduced portal insulin levels")
28
Apr 2026
Hepatitis C infection associated with reduced portal insulin levels
Insulin resistance is a common extrahepatic manifestation of hepatitis C virus (HCV) infection (HCVi), but its mechanism is poorly understood.
-
Life can be betterWe are developing drug products isolated from plant extracts
with history in traditional medicine. -
Improving healthImproving health and wellbeing of the people
is our ultimate goal at Mercury Pharmaceuticals. -
ENTREPRENEURIAL MINDSETHands-on approach to manage projects with proactivity and flexibility.
Welcome to Mercury Pharmaceuticals
We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
OUR Science
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
- NeuroscienceAmong the global leaders in Neuroscience
- OncologyTreatments for niche cancers.
- Research & Development Building a sustainable R&D pipeline.
- Clinical trialsTesting new treatments and ensure their efficacy and safety by conducting clinical trials.
MERCURY trials
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Cancer
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Neuroscience
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
STAY INFORMED!
28
Apr 2026
New clinical guidelines significantly reduce opioid prescriptions after ear surgery
A new retrospective study published in OTO Open, the open-access journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF), demonstrates that the Clinical Practice Guideline (CPG) Opioid Prescribing for Analgesia After Common Otolaryngology Operations has had a measurable and sustained impact on prescribing practices following parotidectomy, which a surgical procedure to remove the parotid gland.
28
Apr 2026
VCU study identifies key factors driving risk of second cancers
Risk of developing a subsequent primary cancer varied significantly by age at initial diagnosis, sex, and type of first cancer, according to a study by Oxana Palesh and Susan Hong and colleagues at Virginia Commonwealth University, U.S., published April 28th in the open-access journal PLOS Medicine.
28
Apr 2026
New AI models quickly find compounds that target Lyme bacteria
Tufts University researchers are using AI and machine learning to more quickly identify potential narrow-spectrum antibiotics to prevent and treat Lyme disease, thanks to a generous gift from an alumnus that sped up their timeline by two to three years.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.